Crohn's disease
Dashboard Shortens Therapy Gaps And Speeds Medication Delivery
Specialty pharmacists at Vanderbilt Health built user-friendly dashboards that have improved the speed of coverage ...
JUNE 15, 2025
FDA Grants New Indication for Omvoh for Moderate to Severe Crohn’s Disease
The FDA has approved mirikizumab (Omvoh, Lilly) as a first-line therapy for moderate to severe Crohn’s ...
MARCH 25, 2025
A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s
This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.
SEPTEMBER 27, 2024
Data From Wearables Can Indicate Flares in Patients With IBD
Data collected by wearables, such as an Apple Watch, Fitbit or Oura Ring, can help uncover flares in people with UC ...
AUGUST 6, 2024
Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s
In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...
JUNE 27, 2024
FDA Grants New Indication Subcutaneous Administration of Entyvio
The FDA approved a new indication for the subcutaneous administration of Entyvio for maintenance therapy in ...
APRIL 22, 2024
FDA Grants New Indication for Rinvoq—Once-Daily Pill for Crohn’s Disease
The FDA granted a new indication for Rinvoq to treat adults with moderate to severe active Crohn’s disease ...
MAY 19, 2023
Study Finds Ustekinumab and Vedolizumab Equally Persistent for Crohn’s After Anti-TNFs
CHARLOTTE, N.C.—Patients with Crohn’s disease who progress from anti–tumor necrosis factor agents ...
JANUARY 19, 2023
3-Drug Regimen With 2 Biologics Deployed in High-Risk Crohn’s Trial
The combination of two monoclonal antibodies targeting different inflammatory mediators plus methotrexate was found ...
SEPTEMBER 14, 2022
Skyrizi indication Expanded for Crohn’s Disease Treatment
AbbVie announced the FDA’s approval of Skyrizi as the first specific interleukin-23 inhibitor for treatment ...
JULY 5, 2022
Deep Remission Not Necessarily Linked To Better Outcomes in Crohn’s
Patients with Crohn’s disease who achieve deep remission one year after combination therapy with infliximab ...
MARCH 19, 2021
IBD Patients Report Their Reactions To Biological Therapies
When IBD patients self-report their adverse reactions to biological therapies, they could provide insights that ...
FEBRUARY 5, 2021
